Phospho-NTRK2 (Y706/Y707) Antibody

What is NTRK2/TrkB and why is Y706/Y707 phosphorylation functionally significant?

NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2), also known as TrkB, is a receptor tyrosine kinase critically involved in the development and maturation of both central and peripheral nervous systems. This transmembrane receptor regulates neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity .

The Y706/Y707 phosphorylation sites (corresponding to Y674/Y675 in TrkA) represent critical activation markers in the TrkB signaling pathway . Upon binding with neurotrophins like BDNF (Brain-Derived Neurotrophic Factor) or NT-4 (Neurotrophin-4), TrkB undergoes homodimerization and autophosphorylation at multiple tyrosine residues, including Y706/Y707 . This phosphorylation is required for the recruitment and activation of downstream effectors including SHC1, FRS2, SH2B1, SH2B2, and PLCG1, which regulate distinct overlapping signaling cascades essential for neuronal function . Through these pathways, phosphorylated TrkB controls the GRB2-Ras-MAPK cascade (regulating neuronal differentiation) and the Ras-PI3 kinase-AKT1 signaling cascade (governing growth and survival) .

What applications are Phospho-NTRK2 (Y706/Y707) antibodies suitable for?

Phospho-NTRK2 (Y706/Y707) antibodies are validated for multiple research applications:

These antibodies demonstrate specific detection of phosphorylated TrkB at Y706/Y707, with minimal cross-reactivity to other proteins or unphosphorylated forms . When implementing these methods, researchers should optimize dilutions for their specific experimental conditions and sample types .

How should Phospho-NTRK2 (Y706/Y707) antibodies be stored and handled for optimal performance?

For maximum stability and activity retention, Phospho-NTRK2 (Y706/Y707) antibodies should be stored at -20°C for long-term preservation (up to one year from receipt) . For frequent use over shorter periods (up to one month), storing at 4°C can provide convenient access while minimizing freeze-thaw cycles .

The antibody formulation typically consists of:

• PBS (Phosphate Buffered Saline) as base buffer

• 50% glycerol as cryoprotectant

• 0.5% BSA (Bovine Serum Albumin) as stabilizer

• 0.02% sodium azide as preservative

To maintain antibody integrity, it is critical to avoid repeated freeze-thaw cycles which can lead to protein denaturation and loss of reactivity . Aliquoting the antibody upon receipt is recommended for applications requiring multiple uses over extended periods .

How can specificity of Phospho-NTRK2 (Y706/Y707) antibodies be validated in experimental systems?

Validating antibody specificity is crucial for accurate interpretation of experimental results. For Phospho-NTRK2 (Y706/Y707) antibodies, multiple validation approaches should be employed:

• Stimulation/Inhibition Controls: Compare samples treated with BDNF (which increases phosphorylation) against those treated with Trk inhibitors like Larotrectinib or Entrectinib . Western blotting should show increased signal with stimulation and decreased signal with inhibition.

• Phosphatase Treatment: Treating samples with phosphatases should eliminate the signal from phospho-specific antibodies while leaving total TrkB signal intact when probed with pan-TrkB antibodies .

• Immunogenic Peptide Controls: Using the synthetic phosphopeptides derived from TrkB around the Y706/Y707 phosphorylation sites as blocking agents should prevent antibody binding and signal detection .

• Cross-validation Using Multiple Techniques: Confirming phosphorylation status using multiple techniques (e.g., mass spectrometry, phospho-protein arrays, and immunoblotting) strengthens validation .

• Fusion Protein Models: Testing antibody specificity against cell lines expressing NTRK fusion proteins versus wild-type proteins can distinguish between different forms of activated receptors .

The phospho-protein arrays described in search result provide an effective platform for systematic analysis of phosphorylation profiles across multiple receptor tyrosine kinases simultaneously, offering an additional validation strategy.

What are the optimal sample preparation methods for detecting phosphorylated NTRK2 (Y706/Y707)?

Successful detection of phosphorylated NTRK2 requires careful sample preparation to preserve phosphorylation status:

• Rapid Sample Processing: Process samples immediately after collection to prevent phosphatase activity. Flash-freezing in liquid nitrogen is recommended when immediate processing is not possible .

• Phosphatase Inhibitors: Inclusion of phosphatase inhibitor cocktails in all buffers is critical. Common inhibitors include sodium orthovanadate, sodium fluoride, sodium pyrophosphate, and β-glycerophosphate .

• Lysis Buffer Composition: Use RIPA or NP-40 based buffers containing:

  • 50mM Tris-HCl (pH 7.4)

  • 150mM NaCl

  • 1% NP-40 or 1% Triton X-100

  • 0.5% sodium deoxycholate

  • 0.1% SDS

  • 1mM EDTA

  • Freshly added protease and phosphatase inhibitors

• Temperature Control: Maintain samples at 4°C during preparation and avoid heating steps that could activate phosphatases .

• Cell Stimulation Protocol: For positive controls, stimulate cells with BDNF (100ng/ml) for 5-15 minutes prior to lysis to maximize phosphorylation signals .

In the context of phospho-protein arrays, tissue lysates are applied directly to nitrocellulose membranes where antibodies against selected kinases are spotted in duplicate, allowing for simultaneous detection of multiple phosphorylated receptors .

How can researchers troubleshoot weak or absent phospho-NTRK2 (Y706/Y707) signals?

When phospho-NTRK2 signals are weak or undetectable, consider the following troubleshooting strategies:

• Confirm Phosphorylation Status: Ensure cells/tissues were in a state where TrkB phosphorylation would be expected. Consider using BDNF stimulation as a positive control (100ng/ml for 5-15 minutes) .

• Verify Total Protein Expression: Check total TrkB expression using pan-TrkB antibodies. Absence of phospho-signal could reflect absence of the receptor itself rather than lack of phosphorylation .

• Review Sample Preparation: Ensure phosphatase inhibitors were present during all preparation steps and samples were kept cold to preserve phosphorylation status .

• Optimize Antibody Concentration: Titrate antibody concentrations. For Western blotting, try 1:500 instead of 1:1000; for IHC/IF consider 1:50 instead of 1:200 .

• Signal Enhancement Techniques:

  • For Western blotting: Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • For IHC/IF: Implement tyramide signal amplification systems

  • For both: Extend primary antibody incubation time to overnight at 4°C

• Check for Unusual Expression Patterns: Some tumors may express underglycosylated, atypically phosphorylated Trk kinases that might be detected differently than expected .

• Cross-validate with Phospho-RTK Arrays: When individual antibody methods fail, phospho-RTK arrays can provide a broader view of receptor tyrosine kinase activation status .

How can phospho-NTRK2 (Y706/Y707) antibodies be applied in cancer research?

Phospho-NTRK2 (Y706/Y707) antibodies have significant applications in cancer research, particularly given the oncogenic potential of TrkB signaling:

• Tumor Classification and Stratification:

  • TrkB is overexpressed in neuroblastoma, prostate adenocarcinoma, and pancreatic ductal adenocarcinoma .

  • In neuroblastomas, overexpression of TrkB correlates with unfavorable prognosis, particularly when accompanied by BDNF overexpression, creating autocrine signaling loops .

  • Phospho-NTRK2 antibodies can help stratify tumors based on activation status rather than merely expression levels .

• Detection of NTRK Fusion-Positive Cancers:

  • While pan-Trk antibodies detect both normal and fusion Trk proteins, phospho-specific antibodies can help identify constitutively active forms that may suggest fusion events .

  • Western blot-like immunoassays using phospho-Trk antibodies can screen NTRK-related tumor biopsies to identify patients with atypical phospho-Trk signals who might benefit from NTRK inhibitors .

• Monitoring Therapeutic Response:

  • Changes in phospho-TrkB levels can indicate response to Trk inhibitors like Larotrectinib or Entrectinib .

  • Sequential biopsies analyzed with phospho-NTRK2 antibodies can document treatment efficacy and detect developing resistance .

• Differentiating Truncated Isoforms:

  • An alternatively spliced truncated TrkB isoform (TrkB-T-Shc) lacks the kinase domain, is not phosphorylated, and may act as a dominant-negative regulator of TrkB signaling .

  • Phospho-specific antibodies can distinguish between kinase-active and truncated forms, providing insight into tumor biology .

Research has shown that atypical constitutive signaling of TrkB kinase and NTRK2-fusion oncogenes can be detected using western blot techniques with anti-phospho-Trk antibodies, making these antibodies valuable tools for identifying patients who might benefit from TrkB-targeted therapies .

What are the considerations for using phospho-NTRK2 (Y706/Y707) antibodies in neuroscience research?

In neuroscience research, phospho-NTRK2 (Y706/Y707) antibodies provide valuable insights into neurotrophin signaling dynamics:

• Synaptic Plasticity Studies:

  • TrkB signaling through PLCG1 and downstream protein kinase C-regulated pathways controls synaptic plasticity .

  • Phospho-NTRK2 antibodies can track receptor activation during long-term potentiation experiments, correlating molecular activation with electrophysiological measurements .

• Neuron-Glia Communication:

  • TrkB may play a role in neurotrophin-dependent calcium signaling in glial cells and mediate neuron-glia communication .

  • Phospho-specific antibodies can identify activated TrkB in different cell types within complex neural tissues.

• Neuronal Development and Differentiation:

  • Through SHC1, FRS2, SH2B1, SH2B2, activated TrkB controls the GRB2-Ras-MAPK cascade regulating neuronal differentiation .

  • Temporal mapping of TrkB phosphorylation during development can elucidate critical periods for neurotrophin sensitivity.

• Technical Considerations for Neural Tissue:

  • For immunohistochemistry in brain tissue, dilutions of 1:200-1:800 have been validated .

  • Verified samples include mouse spinal marrow and rat brain .

  • Fixation methods significantly impact epitope accessibility; mild fixation (4% PFA for shorter durations) may better preserve phospho-epitopes.

• Combinatorial Approach with Neuronal Markers:

  • Co-staining with markers like Nestin (for neural progenitors) or NeuN (for mature neurons) can provide cellular context for phospho-TrkB signals .

  • In glioblastoma research, phospho-TrkB has been detected in Nestin-positive cells, suggesting activation in tumor stem-like cells .

These applications highlight the importance of phospho-NTRK2 antibodies in understanding the molecular mechanisms underlying learning, memory, and neuronal survival in both normal and pathological conditions.

How do phospho-protein arrays complement traditional phospho-NTRK2 antibody applications?

Phospho-protein arrays represent an advanced approach that complements traditional single-antibody methods:

Researchers studying NTRK2 phosphorylation in complex biological contexts (e.g., tumors with multiple activated signaling pathways) can use arrays as an initial screening tool followed by focused investigation with specific phospho-NTRK2 antibodies.

How can researchers address cross-reactivity issues between NTRK family members when using phospho-specific antibodies?

Cross-reactivity between highly conserved NTRK family members poses a significant challenge for specific detection:

• Understanding Sequence Homology:

  • The phosphorylation sites are conserved between TrkA and TrkB: Tyr674/675 of TrkA corresponds to Tyr706/707 in TrkB .

  • Some antibodies specifically target phospho-TrkB Y706/Y707, while others detect all phosphorylated Trk family members (TrkA Y674/675, TrkB Y706/707, TrkC Y709) .

• Selective Validation Approaches:

  • Knockout/knockdown controls: Comparing signals in cells with NTRK2 knockdown versus control cells can confirm specificity.

  • Recombinant protein controls: Testing antibodies against purified phosphorylated recombinant proteins of each Trk family member.

  • Peptide competition assays using phospho-peptides specific to each Trk member's activation loop.

• Technical Solutions:

  • For Western blotting, molecular weight discrimination can help differentiate between TrkA (~140 kDa), TrkB (~145 kDa), and TrkC (~145-150 kDa) .

  • Sequential immunoprecipitation with isoform-specific antibodies followed by phospho-detection.

  • When absolute specificity is required, consider using multiple antibodies targeting different epitopes or orthogonal techniques like mass spectrometry.

• Application-Specific Considerations:

  • In tissues with known expression patterns (e.g., TrkB predominant in brain), cross-reactivity concerns may be less critical.

  • In samples with mixed expression, interpret results cautiously and validate with isoform-specific approaches.

• Commercial Antibody Selection:

  • Some antibodies like Cell Signaling Technology's C50F3 (mAb #4621) are designed to detect both phospho-TrkA (Tyr674/675) and phospho-TrkB (Tyr706/707) .

  • Others like Boster Bio's A01388Y706-1 claim specificity for phospho-TrkB (Y706) with no cross-reactivity to other proteins .

When research questions require absolute discrimination between phosphorylated Trk family members, using isoform-specific antibodies or orthogonal methods is recommended.

What are the best practices for quantifying phospho-NTRK2 levels relative to total NTRK2 expression?

Accurate quantification of phosphorylation status requires careful normalization strategies:

The recommended dilutions for quantitative applications are: Western blotting (1:500-1:1000), immunofluorescence (1:50-1:200), and ELISA (1:10000) .

How can researchers distinguish between normal activation and pathological constitutive phosphorylation of NTRK2?

Distinguishing physiological from pathological NTRK2 activation is crucial for accurate interpretation:

• Temporal Dynamics Assessment:

  • Normal Activation: Typically transient, showing rapid increase followed by gradual decrease after neurotrophin stimulation.

  • Constitutive Activation: Persistent phosphorylation independent of ligand availability or stimulation time.

  • Experimental Approach: Time-course experiments comparing ligand-stimulated versus unstimulated samples across multiple timepoints.

• Ligand Dependency Testing:

  • Normal Activation: Requires presence of neurotrophins (BDNF or NT-4).

  • Constitutive Activation: Persists in serum-starved conditions or in presence of neurotrophin-neutralizing antibodies.

  • Experimental Approach: Compare phosphorylation levels in serum-starved conditions with and without BDNF neutralizing antibodies.

• Inhibitor Response Profiling:

  • Normal Activation: Responsive to both Trk inhibitors (e.g., Larotrectinib) and upstream regulators.

  • Constitutive Activation: May show resistance to regulatory mechanisms but remain sensitive to direct Trk inhibitors.

  • Experimental Approach: Dose-response studies with Trk inhibitors like Larotrectinib or Entrectinib .

• Molecular Weight and Glycosylation Assessment:

  • Normal TrkB: Fully glycosylated, appearing at ~145 kDa.

  • Pathological Forms: May include underglycosylated variants or fusion proteins with altered molecular weights.

  • Experimental Approach: Western blotting with careful molecular weight analysis and glycosylation assessment .

• Downstream Signaling Pattern Analysis:

  • Normal Activation: Balanced activation of multiple downstream pathways.

  • Oncogenic Activation: Often shows preferential activation of specific survival or proliferation pathways.

  • Experimental Approach: Phospho-protein arrays to assess multiple signaling nodes simultaneously .

Research has identified atypical underglycosylated, phospho-active Trk kinase signals in glioblastoma biopsies that were not present in normal brain samples, highlighting the importance of these distinctions for potential therapeutic targeting with NTRK inhibitors .

How are phospho-NTRK2 antibodies being used to identify patients for NTRK inhibitor therapies?

Phospho-NTRK2 antibodies are emerging as valuable tools in precision oncology:

• Biomarker Development for Drug Response:

  • Screening methodologies using western blot-like immunoassays with anti-phospho-Trk antibodies can identify patients with atypical panTrk or phospho-Trk signals who might benefit from NTRK inhibitors .

  • This approach is particularly valuable for brain tumors where detection of NTRK-related abnormalities is challenging using conventional methods .

• Distinguishing Fusion from Overexpression:

  • NTRK gene fusions represent actionable targets for TRK inhibitors, but overexpression of wild-type receptors may also drive tumor progression.

  • Phospho-antibodies can help identify constitutively active receptors regardless of the underlying mechanism .

• Response Monitoring:

  • Serial sampling and phospho-NTRK2 antibody analysis can track treatment efficacy.

  • Persistence or reemergence of phospho-signals despite treatment might indicate developing resistance mechanisms.

• Technical Implementation in Clinical Settings:

  • Immunohistochemistry protocols using phospho-NTRK2 antibodies at dilutions of 1:50-1:300 have been validated for formalin-fixed paraffin-embedded tissues .

  • Western blotting of fresh-frozen samples provides quantitative assessment of activation status .

• Integrated Diagnostic Approach:

  • Combined assessment with multiple antibodies (phospho-specific, pan-Trk, and isoform-specific) provides a more complete picture of NTRK alterations.

  • This multi-antibody approach can complement molecular testing methods like FISH, NGS, or RT-PCR for NTRK fusion detection.

As Trk inhibitors like Larotrectinib and Entrectinib show promising response rates in NTRK fusion-positive cancers, the ability to identify patients most likely to benefit using phospho-NTRK2 antibodies represents an important advancement in precision oncology .

What recent advances have been made in phospho-proteomic approaches involving NTRK2?

Phospho-proteomic technologies have significantly advanced the study of NTRK2 signaling:

• Advanced Array Technologies:

  • Commercially available phospho-protein arrays now enable analyses of phosphorylation profiles of receptor tyrosine kinases and their downstream signaling proteins in tumor tissue samples .

  • These arrays can be used for single sample analysis, serial sample monitoring, and hierarchical clustering of tumors based on phosphorylation patterns .

• Mass Spectrometry-Based Approaches:

  • Phospho-enrichment strategies coupled with high-resolution mass spectrometry can identify specific phosphorylation sites and their stoichiometry.

  • These approaches provide comprehensive mapping of phosphorylation events beyond the canonical activation sites.

• Single-Cell Phospho-Profiling:

  • Emerging technologies enable assessment of TrkB phosphorylation at the single-cell level, revealing population heterogeneity within tumors or neural tissues.

  • This approach can identify rare subpopulations with distinct activation patterns.

• Spatial Phospho-Proteomics:

  • Techniques combining laser capture microdissection with phospho-proteomics preserve spatial information about receptor activation.

  • This is particularly valuable for understanding NTRK2 signaling in complex tissues like brain.

• Computational Integration Approaches:

  • Systems biology methods integrating phospho-proteomic data with transcriptomics and genomics provide a holistic view of NTRK2 signaling networks.

  • These approaches can predict therapeutic vulnerabilities and resistance mechanisms.

The systematic analysis of phospho-protein arrays demonstrates important aspects of data processing and evaluation, including normalization strategies and validation requirements that enhance the robustness of findings in personalized clinical medicine contexts .

How can phospho-NTRK2 antibodies contribute to understanding the role of TrkB in neurodevelopmental and psychiatric disorders?

Phospho-NTRK2 antibodies offer unique insights into the molecular basis of neuropsychiatric conditions:

• Neurodevelopmental Process Mapping:

  • TrkB signaling regulates neuron survival, proliferation, migration, differentiation, and synapse formation during development .

  • Phospho-NTRK2 antibodies can track activation patterns during critical developmental windows.

  • Alterations in these patterns may underlie neurodevelopmental disorders.

• Synaptic Plasticity in Learning and Memory:

  • TrkB activation controls synaptic plasticity through PLCG1 and protein kinase C-regulated pathways .

  • Phospho-NTRK2 antibodies can monitor receptor activation during learning and memory processes.

  • This approach helps elucidate molecular mechanisms of cognitive dysfunction in psychiatric disorders.

• Mood Disorder Research Applications:

  • Mutations in NTRK2 have been associated with mood disorders .

  • Phospho-antibodies can help characterize how these mutations affect signaling activation patterns.

  • This may reveal mechanistic insights into how antidepressants modulate BDNF-TrkB signaling.

• Methodological Considerations for Brain Research:

  • Brain samples require specific handling to preserve phosphorylation status.

  • For immunohistochemistry in rodent brain tissues, dilutions of 1:200-1:800 have been validated .

  • Post-mortem human samples present additional challenges requiring rapid processing protocols.

• Integration with Genetic Findings:

  • Combining phospho-TrkB analysis with genetic data (e.g., NTRK2 variants) provides functional context to genomic findings.

  • This integrated approach can help classify variants of uncertain significance in neuropsychiatric genetics.

By facilitating the molecular characterization of TrkB signaling in neural tissues, phospho-NTRK2 antibodies contribute to a deeper understanding of how altered neurotrophin signaling contributes to conditions ranging from autism spectrum disorders to mood disorders and schizophrenia.